Clinical review report. Tesamorelin (Egrifta) : indication : treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference [greater than or equal to] 95 cm for males and [greater than or equal to] 94 cm for females, and confirmed by a VAT level > 130 cm² by computerized tomography scan, in treatment-experienced adult human immunodeficiency virus-infected patients with lipodystrophy.

Clinical review report. indication : treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference [greater than or equal to] 95 cm for males and [greater than or equal to] 94 cm for females, and confirmed by a VAT level > 130 cm² by computerized tomography scan, in treatment-experienced adult human immunodeficiency virus-infected patients with lipodystrophy. Tesamorelin (Egrifta) :

Show other versions (1)

Human immunodeficiency virus (HIV)-associated lipodystrophy is a medical condition characterized by body composition changes, including lipohypertrophy. Patients with lipohypertrophy typically have excess visceral adipose tissue (VAT) in the abdomen, but may also accumulate fat in other areas of the...

Full description

Saved in:
Bibliographic Details
Online Access: Full text
Format: Electronic eBook
Language:English
Published: Ottawa (ON) : CADTH, 2016
Series:Common drug review clinical review report.
Subjects:
HIV-Associated Lipodystrophy Syndrome > drug therapy.
Intra-Abdominal Fat > drug effects.
Growth Hormone-Releasing Hormone > therapeutic use.
Growth Hormone-Releasing Hormone > adverse effects.
Treatment Outcome.
Canada.
Systematic Review.
Tables.

Internet

Full text

Similar Items